Document is current
Any future updates will be listed below
-
Authors
Bartolomeo, Nicolò
Schuetz, Yannic Pannatier
Nascimbeni, Anna Chiara
Castro, Daniela Gallo
Crozat, Baptiste
Barry, Mamadou Pathé
Ambresin, Aude
-
Funding
Funding for this research was provided by:
Bayer (Schweiz) AG
- License Information
-
More Information
Article History
Received: 15 July 2025
Accepted: 27 August 2025
First Online: 19 September 2025
Declarations
:
: Aude Ambresin: consultant for Bayer, Novartis, Roche, Apellis and Earlysight; lecturer fees from Optovue, Abbvie, Novartis, Bayer, Roche, Apellis, Astellas and RetinAi. Nicolò Bartolomeo, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, Daniela Gallo Castro, Baptiste Crozat and Mamadou Pathé Barry have nothing to disclose.
: The study design was approved by the local ethics committee (Commission cantonale d'éthique de la recherche sur l'être humain CER-VD -part of Swissethics) for data collection and analysis (CERVD: 2024–01491) and was conducted in accordance with the Declaration of Helsinki. Clinical trial no.: not applicable.
